Inactive Instrument

Achaogen Inc Stock price Nasdaq

Equities

US0044491043

Sales 2017 11.18M Sales 2018 8.73M Capitalization 56.73M
Net income 2017 -126M Net income 2018 -187M EV / Sales 2017 28 x
Net cash position 2017 143M Net Debt 2018 18.83M EV / Sales 2018 8.66 x
P/E ratio 2017
-3.39 x
P/E ratio 2018
-0.29 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Corporate Officer/Principal - 18-07-31
Corporate Officer/Principal - 19-06-29
Members of the board TitleAgeSince
Director/Board Member 72 15-03-12
More insiders
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Achaogen
  4. Stock Achaogen Inc - Nasdaq